keyword
https://read.qxmd.com/read/38650040/clinical-pathologic-and-genomic-characteristics-of-two-pediatric-glioneuronal-tumors-with-a-clip2-met-fusion
#1
JOURNAL ARTICLE
Nicholas Chapman, Joshua Greenwald, Jolee Suddock, Dong Xu, Alexander Markowitz, Maeve Humphrey, Jennifer A Cotter, Mark D Krieger, Debra Hawes, Jianling Ji
Integration of molecular data with histologic, radiologic, and clinical features is imperative for accurate diagnosis of pediatric central nervous system (CNS) tumors. Whole transcriptome RNA sequencing (RNAseq), a genome-wide and non-targeted approach, allows for the detection of novel or rare oncogenic fusion events that contribute to the tumorigenesis of a substantial portion of pediatric low- and high-grade glial and glioneuronal tumors. We present two cases of pediatric glioneuronal tumors occurring in the occipital region with a CLIP2::MET fusion detected by RNAseq...
April 22, 2024: Acta Neuropathologica Communications
https://read.qxmd.com/read/38636352/serum-brain-derived-neurotrophic-factor-val66met-polymorphism-and-open-label-ssri-treatment-response-in-major-depressive-disorder
#2
JOURNAL ARTICLE
Anna J T Smit, Gwyneth W Y Wu, Ryan Rampersaud, Victor I Reus, Owen M Wolkowitz, Synthia H Mellon
BACKGROUND: Brain-derived neurotrophic factor (BDNF) has been implicated in the therapeutic action of antidepressants and possibly in the pathophysiology of Major Depressive Disorder (MDD). Clinical studies of peripheral blood levels of BDNF in MDD have provided conflicting results, and there are also conflicting reports regarding the predictive value of peripheral BDNF levels for antidepressant treatment response. The present study investigated the association between serum BDNF levels, the BDNF Val66Met polymorphism (rs6265), clinical characteristics and SSRI treatment response...
April 6, 2024: Psychoneuroendocrinology
https://read.qxmd.com/read/38626023/predictors-of-multiple-sclerosis-progression-a-systematic-review-of-conventional-magnetic-resonance-imaging-studies
#3
JOURNAL ARTICLE
Nima Broomand Lomer, Kamal AmirAshjei Asalemi, Alia Saberi, Kasra Sarlak
INTRODUCTION: Multiple Sclerosis (MS) is a chronic neurodegenerative disorder that affects the central nervous system (CNS) and results in progressive clinical disability and cognitive decline. Currently, there are no specific imaging parameters available for the prediction of longitudinal disability in MS patients. Magnetic resonance imaging (MRI) has linked imaging anomalies to clinical and cognitive deficits in MS. In this study, we aimed to evaluate the effectiveness of MRI in predicting disability, clinical progression, and cognitive decline in MS...
2024: PloS One
https://read.qxmd.com/read/38617664/identification-of-novel-quinolone-and-quinazoline-alkaloids-as-phosphodiesterase-10a-inhibitors-for-parkinson-s-disease-through-a-computational-approach
#4
JOURNAL ARTICLE
Iqra Ahmad, Hira Khalid, Asia Perveen, Muhammad Shehroz, Umar Nishan, Faiz Ur Rahman, Sheheryar, Arlindo Alencar Moura, Riaz Ullah, Essam A Ali, Mohibullah Shah, Suvash Chandra Ojha
Phosphodiesterases (PDEs) are vital in signal transduction, specifically by hydrolyzing cAMP and cGMP. Within the PDE family, PDE10A is notable for its prominence in the striatum and its regulatory function over neurotransmitters in medium-spiny neurons. Given the dopamine deficiency in Parkinson's disease (PD) that affects striatal pathways, PDE10A inhibitors could offer therapeutic benefits by modulating D1 and D2 receptor signaling. This study was motivated by the successful history of quinazoline/quinazoline scaffolds in the inhibition of PDE10A...
April 9, 2024: ACS Omega
https://read.qxmd.com/read/38606777/apilimod-dimesylate-in-c9orf72-amyotrophic-lateral-sclerosis-a-randomized-phase-2a-clinical-trial
#5
JOURNAL ARTICLE
Suma Babu, Katharine A Nicholson, Jeffrey D Rothstein, Andrea Swenson, Paul J Sampognaro, Pravin Pant, Eric A Macklin, Susan Spruill, Sabrina Paganoni, Tania F Gendron, Mercedes Prudencio, Leonard Petrucelli, Darrell Nix, Sean Landrette, Esther Nkrumah, Keith Fandrick, Joan Edwards, Peter R Young
Apilimod dimesylate is a first-in-class phosphoinositide kinase, FYVE-type zinc finger containing (PIKfyve) inhibitor with favourable clinical safety profile and has demonstrated activity in preclinical C9orf72 and TDP-43 amyotrophic lateral sclerosis models. In this amyotrophic lateral sclerosis clinical trial, the safety, tolerability, CNS penetrance, and modulation of pharmacodynamic target engagement biomarkers were evaluated. This Phase 2a, randomized, double-blind, placebo-controlled, biomarker-endpoint clinical trial was conducted in four USA centres (ClinicalTrials...
April 12, 2024: Brain
https://read.qxmd.com/read/38605928/targeted-therapeutic-options-in-early-and-metastatic-nsclc-overview
#6
REVIEW
Gabriella Gálffy, Éva Morócz, Réka Korompay, Réka Hécz, Réka Bujdosó, Rita Puskás, Tímea Lovas, Eszter Gáspár, Kamel Yahya, Péter Király, Zoltán Lohinai
The complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measured in years...
2024: Pathology Oncology Research: POR
https://read.qxmd.com/read/38603654/cns-antitumor-activity-of-amivantamab-with-osimertinib-in-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer-with-acquired-mesenchymal-epithelial-transition-amplification-resistance-mechanism-a-case-report
#7
JOURNAL ARTICLE
Ebaa Al-Obeidi, Karen Kelly, David R Gandara, Jonathan W Riess
NSCLC w/EGFRex19del & MET amp: durable intracranial + systemic response to amivantamab/osimertinib.
April 2024: JCO Precision Oncology
https://read.qxmd.com/read/38583173/case-series-of-multicontact-peripheral-nerve-stimulation-in-the-transversus-abdominis-plane-for-chronic-abdominal-wall-pain
#8
JOURNAL ARTICLE
Caroline Eden, Ramanjot S Kang, Ankur A Patel, Amitabh Gulati
OBJECTIVES: Managing abdominal pain can be difficult. This is due to the nonspecific nature of the pain, the multiple etiologies, and the different mechanisms underlying this type of pain. Abdominal wall pain in particular poses its own challenges. Traditionally, chronic abdominal wall pain has been managed with nonopioid analgesics, and in severe cases, opioid therapy has been considered. For patients with chronic abdominal wall pain refractory to medication management, peripheral nerve blocks and spinal cord stimulation also have been trialed with some success...
April 5, 2024: Neuromodulation: Journal of the International Neuromodulation Society
https://read.qxmd.com/read/38569875/validation-of-the-international-mogad-panel-proposed-criteria-a-single-centre-us-study
#9
JOURNAL ARTICLE
Angeliki G Filippatou, Yana Said, Haiwen Chen, Eleni S Vasileiou, Gelareh Ahmadi, Elias S Sotirchos
BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system. We aimed to evaluate the diagnostic performance of recently proposed MOGAD diagnostic criteria in a real-world patient cohort at a tertiary referral centre. METHODS: We identified all patients who were evaluated at Johns Hopkins and were MOG-IgG seropositive by cell-based assay. We retrospectively applied the proposed MOGAD diagnostic criteria...
April 3, 2024: Journal of Neurology, Neurosurgery, and Psychiatry
https://read.qxmd.com/read/38551913/brain-connectivity-changes-underlying-depression-and-fatigue-in-relapsing-remitting-multiple-sclerosis-a-systematic-review
#10
JOURNAL ARTICLE
Agniete Kampaite, Rebecka Gustafsson, Elizabeth N York, Peter Foley, Niall J J MacDougall, Mark E Bastin, Siddharthan Chandran, Adam D Waldman, Rozanna Meijboom
Multiple Sclerosis (MS) is an autoimmune disease affecting the central nervous system, characterised by neuroinflammation and neurodegeneration. Fatigue and depression are common, debilitating, and intertwined symptoms in people with relapsing-remitting MS (pwRRMS). An increased understanding of brain changes and mechanisms underlying fatigue and depression in RRMS could lead to more effective interventions and enhancement of quality of life. To elucidate the relationship between depression and fatigue and brain connectivity in pwRRMS we conducted a systematic review...
2024: PloS One
https://read.qxmd.com/read/38543223/navigating-the-nose-to-brain-route-a-systematic-review-on-lipid-based-nanocarriers-for-central-nervous-system-disorders
#11
REVIEW
Edoardo Agosti, Marco Zeppieri, Sara Antonietti, Luigi Battaglia, Tamara Ius, Caterina Gagliano, Marco Maria Fontanella, Pier Paolo Panciani
BACKGROUND: The blood-brain barrier (BBB) regulates brain substance entry, posing challenges for treating brain diseases. Traditional methods face limitations, leading to the exploration of non-invasive intranasal drug delivery. This approach exploits the direct nose-to-brain connection, overcoming BBB restrictions. Intranasal delivery enhances drug bioavailability, reduces dosage, and minimizes systemic side effects. Notably, lipid nanoparticles, such as solid lipid nanoparticles and nanostructured lipid carriers, offer advantages like improved stability and controlled release...
February 27, 2024: Pharmaceutics
https://read.qxmd.com/read/38540110/novel-interventions-on-comorbidities-in-patients-with-fetal-alcohol-spectrum-disorder-fasd-an-integrative-review
#12
REVIEW
Vicente Andreu-Fernández, Nunzia La Maida, Maribel Marquina, Afrouz Mirahi, Oscar García-Algar, Simona Pichini, Adele Minutillo
Prenatal exposure to alcohol can cause Fetal Alcohol Spectrum Disorders (FASDs) after birth, encompassing a spectrum of physical, cognitive, and behavioral abnormalities. FASD represents a severe non-genetic disability avoidable through alcohol abstinence during pregnancy and when planning it. Clinical severity depends on alcohol impact, symptomatology, and resulting disabilities. FASD is a permanent disability with no recognized specific medical care. Conversely, secondary FASD-related disabilities can be symptomatically treated...
February 22, 2024: Biomedicines
https://read.qxmd.com/read/38537509/functional-electrical-stimulation-combined-with-voluntary-cycling-accentuates-vo-2-response-in-people-with-severe-multiple-sclerosis-a-pilot-study
#13
JOURNAL ARTICLE
Suzanne Máté, Nicholas Corr, Daniel Hackett, Michael Barnett, Maria Fiatarone Singh, Ché Fornusek
BACKGROUND: Lower limb muscle weakness and reduced balance due to disease progression in multiple sclerosis (MS) may make robust aerobic exercise difficult. Functional electrical stimulation (FES) cycling combined with voluntary cycling may allow people with severe MS to enhance the intensity of aerobic exercise. The aim of this study was to investigate the cardiorespiratory, power, and participant-reported perceptions during acute bouts of FES cycling, voluntary cycling, and FES cycling combined with voluntary cycling (FES assist cycling)...
March 20, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38529033/probable-secondary-hemophagocytic-lymphohistiocytosis-manifesting-as-central-nervous-system-lesions-after-covid-19-vaccination-a-case-report
#14
Ju Hye Kim, Ji Yeon Chung, Jeong Bin Bong
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rare systemic inflammatory disease commonly characterized by histiocyte infiltration in multiple organs, such as the liver, spleen, lymph nodes, bone marrow, and central nervous system. The clinical features of HLH include fever, splenomegaly, cytopenia, hypertriglyceridemia, hypofibrinogenemia, and elevated blood ferritin levels. HLH is categorized as either primary or secondary. Coronavirus disease 2019 (COVID-19) vaccines may occasionally trigger secondary HLH, which is related to hyperinflammatory syndrome...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38498623/preoperative-11-c-methionine-pet-mri-in-pediatric-infratentorial-tumors
#15
JOURNAL ARTICLE
Pierre-Aurélien Beuriat, Anthime Flaus, Aurélie Portefaix, Alexandru Szathmari, Marc Janier, Marc Hermier, Sylvie Lorthois-Ninou, Christian Scheiber, Sibel Isal, Nicolas Costes, Ines Merida, Sophie Lancelot, Alexandre Vasiljevic, Pierre Leblond, Cécile Faure Conter, Clarisse Saunier, Behrouz Kassai, Matthieu Vinchon, Federico Di Rocco, Carmine Mottolese
PURPOSE: MRI is the main imaging modality for pediatric brain tumors, but amino acid PET can provide additional information. Simultaneous PET-MRI acquisition allows to fully assess the tumor and lower the radiation exposure. Although symptomatic posterior fossa tumors are typically resected, the patient management is evolving and will benefit from an improved preoperative tumor characterization. We aimed to explore, in children with newly diagnosed posterior fossa tumor, the complementarity of the information provided by amino acid PET and MRI parameters and the correlation to histopathological results...
March 25, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38497149/efficacy-of-intravenous-high-dose-methotrexate-in-preventing-relapse-to-the-central-nervous-system-in-r-chop-like-treated-high-risk-diffuse-large-b-cell-lymphoma-patients-and-its-effect-on-mortality-a-systematic-review-and-meta-analysis
#16
JOURNAL ARTICLE
Elisabeth R Tolley, Christian Lewinter, Lars M Pedersen, Torsten Holm Nielsen
UNLABELLED: CNS relapse in patients with diffuse large B-cell lymphoma (DLBCL) carries a dismal prognosis with most clinical guidelines recommending CNS prophylaxis to patients deemed at high risk for CNS relapse. However, results from observational studies investigating the effect of CNS prophylaxis have yielded conflicting results. OBJECTIVES: To evaluate: 1) whether addition of prophylactic intravenous HD-MTX reduces the risk of CNS relapse in high-risk DLBCL patients treated with R-CHOP or similar and 2) whether HD-MTX prophylaxis confers an overall survival benefit, irrespective of CNS relapse...
March 14, 2024: Haematologica
https://read.qxmd.com/read/38490447/genetically-distinct-oligosarcoma-arising-from-oligodendroglioma-systematic-review-illustrative-case-example
#17
JOURNAL ARTICLE
Alexander Evans, Kiana Y Prather, James Battiste, Kar-Ming Fung, Ian F Dunn, Christopher S Graffeo
BACKGROUND: Oligosarcoma is a rare central nervous system (CNS) neoplasm that may arise following oligodendroglioma resection, which demonstrates a unique genetic profile and aggressive clinical phenotype. We present a systematic review and illustrative case example emphasizing the clinical and prognostic features of this unusual and unfavorable neuro-oncologic disease. METHODS: Systematic literature review and illustrative case report. RESULTS: A 41-year-old man who had undergone two neurosurgical resections for a WHO grade II oligodendroglioma (Ki-67=5-10%, 1p/19q co-deleted, IDH2 mutated), without adjuvant chemoradiation, presented with seizures seven years after resection...
March 13, 2024: World Neurosurgery
https://read.qxmd.com/read/38487578/association-between-cns-active-drugs-and-risk-of-alzheimer-s-and-age-related-neurodegenerative-diseases
#18
JOURNAL ARTICLE
Helena Cortes-Flores, Georgina Torrandell-Haro, Roberta Diaz Brinton
OBJECTIVE: As neuropsychiatric conditions can increase the risk of age-related neurodegenerative diseases (NDDs), the impact of CNS-active drugs on the risk of developing Alzheimer's Disease (AD), non-AD dementia, Multiple Sclerosis (MS), Parkinson's Disease (PD) and Amyotrophic Lateral Sclerosis (ALS) was investigated. RESEARCH DESIGN AND METHODS: A retrospective cohort analysis of a medical claims dataset over a 10 year span was conducted in patients aged 60 years or older...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38482514/investigating-the-impact-of-polypharmacy-and-anticholinergic-medication-burden-on-objective-cognitive-performance-in-adults-with-multiple-sclerosis
#19
JOURNAL ARTICLE
Joanie Huebner, Jade Robichaud, Julia S Cozart, Crystal Burkhardt, Sharon G Lynch, Jared M Bruce
BACKGROUND: Polypharmacy, or the use of 5 or more daily medications, is common in adults with multiple sclerosis (MS), and is often due to various physical, cognitive, and emotional symptoms. However, research regarding the association between polypharmacy and cognitive outcomes in MS is sparse. Furthermore, individuals with MS often use medications with anticholinergic properties, which are commonly associated with cognitive impairment and other central nervous system adverse effects...
2024: International Journal of MS Care
https://read.qxmd.com/read/38461731/feasibility-study-to-assess-lesion-repair-in-relapsing-remitting-multiple-sclerosis-a-randomized-controlled-pilot-clinical-trial-of-domperidone-add-on-treatment
#20
JOURNAL ARTICLE
Yunyan Zhang, Wei-Qiao Liu, Zahra Hosseinpour, G Bruce Pike, Graziela Cerchiaro, Jamie Greenfield, V Wee Yong, Luanne M Metz
BACKGROUND: Identification of therapies to promote repair in multiple sclerosis is challenged by the lack of an accepted trial model and associated outcome measures. The goal of this study was to determine the feasibility of a new trial model that enrolls disease modifying therapy (DMT)-treated relapsing-remitting multiple sclerosis (RRMS) participants who have enhancing lesions on clinically indicated brain MRI, and to explore estimates of lesion repair using MRI. METHODS: This was a single site randomized controlled clinical trial...
February 27, 2024: Multiple Sclerosis and related Disorders
keyword
keyword
115034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.